References
Meunier F, Aoun M, Gerard M Therapy for oropharyngeal candidiasis in the immunocompromised host: A randomized double-blind study of fluconazole vs. ketoconazole. Reviews of Infectious Diseases 1990, 12, Supplement 3: 364–368.
Fisher MA, Shen SH, Haddad J, Tarry WF Comparison of in vivo activity of fluconazole with that of amphotericin B againstCandida tropicalis, Candida glabrata, andCandida krusei. Antimicrobial Agents and Chemotherapy 1989, 33: 1443–1446.
Roder BL, Sonnenschein C, Hartzen SH Failure of fluconazole therapy inCandida krusei fungemia. European Journal of Clinical Microbiology and Infectious Diseases 1991, 10: 173.
Brajtburg J, Powderly WG, Kobayashi GS, Medoff G Amphotericin B: current understanding of mechanisms of action. Antimicrobial Agents and Chemotherapy 1990, 34: 183–188.
Samonis G, Rolston K, Karl C, Miller P, Bodey GP Prophylaxis of oropharyngeal candidiasis with fluconazole. Reviews of Infectious Diseases 1990, 12, Supplement 3: 369–370.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Akova, M., Akalin, H.E., Uzun, Ö. et al. Emergence ofCandida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur. J. Clin. Microbiol. Infect. Dis. 10, 598–599 (1991). https://doi.org/10.1007/BF01967286
Issue Date:
DOI: https://doi.org/10.1007/BF01967286